Keywords:
Asthma.
;
Electronic books.
Description / Table of Contents:
This book presents an overview on multidimensional profiling strategies and visualization approaches for phenotyping asthma. It includes cutting-edge methods and protocols and provides step-by-step detail essential for reproducible results.
Type of Medium:
Online Resource
Pages:
1 online resource (353 pages)
Edition:
1st ed.
ISBN:
9781461486039
Series Statement:
Advances in Experimental Medicine and Biology Series ; v.795
URL:
https://ebookcentral.proquest.com/lib/geomar/detail.action?docID=1697688
DDC:
616.238
Language:
English
Note:
Intro -- Preface Application of Translational Science to the Clinical Problem of Asthma -- The Problem -- Molecular Profiling and Personalized Medicine -- Motivation -- References -- Contents -- Part I: The Spectrum of Asthma: An Introduction -- References -- Chapter 1: Introduction to Asthma and Phenotyping -- 1.1 Introduction and Primer on Asthma and Its Heterogeneity -- 1.2 Phenotyping Strategies -- 1.3 Application of Clinical Asthma Phenotypes -- 1.3.1 US Severe Asthma Research Program -- 1.3.2 Allergic Asthma -- 1.3.3 Exercise-Induced Asthma -- 1.3.4 Induced Phenotype -- 1.4 Cellular Phenotyping -- 1.5 Molecular Phenotyping -- 1.5.1 Molecular Phenotyping Based on Gene Expression -- 1.5.2 Molecular Phenotyping Based on Protein Expression -- 1.6 Summary -- References -- Chapter 2: Epidemiology of Asthma: Prevalence and Burden of Disease -- 2.1 Introduction to Asthma Epidemiology -- 2.2 Sources of Data and Methods of Surveillance -- 2.2.1 USA -- 2.2.2 Global Surveillance -- 2.2.3 Limitations of Surveillance Methods -- 2.3 Prevalence of Asthma: USA -- 2.4 Prevalence of Asthma: Global -- 2.5 From Bench to Bedside: Inner-City Asthma Consortium -- 2.6 From Bench to Curbside: Public Health Implications -- 2.7 Summary -- References -- Chapter 3: Heterogeneity of Asthma in Society -- 3.1 Key Epidemiologic Factors and Influences on Asthma -- 3.2 Role of Urbanization -- 3.2.1 Increased Asthma in Urban Setting: Case for Local Factors -- 3.2.2 Conflicting Results: Rural Versus Urban Asthma Debate -- 3.3 Obesity -- 3.3.1 Correlative Studies of Obesity and Asthma -- 3.3.2 Mechanisms of Effect of Obesity on Asthma -- 3.3.3 Treatment Considerations in Obese Asthmatics -- 3.4 Vitamin D -- 3.4.1 Relationship of Vitamin D and Pediatric Asthma -- 3.4.2 Adult Vitamin D and Asthma -- 3.4.3 Mechanisms of Vitamin D Modulation of Asthma.
,
3.4.4 Treatment Considerations -- 3.5 Summary -- References -- Chapter 4: Inhaled Environmental Allergens and Toxicants as Determinants of the Asthma Phenotype -- 4.1 The Relationship of Allergen Exposure to Asthma Prevalence, Triggers, and Phenotypes -- 4.1.1 Seasonal Asthma and Allergen Prevalence: The Seasonal Asthmatic Phenotype -- 4.1.2 Mechanisms of IgE-Mediated Allergic Responses as an Asthma Phenotype Determinant -- 4.1.3 Pollen as a Critical Allergen Facilitator of the Asthmatic Phenotype -- 4.1.4 Adaptive vs. Innate Immune Responses: Contribution to Heterogeneous Asthma Phenotype -- 4.2 Gaseous, Volatile, and Particulate Environmental Triggers as Determinants of the Asthmatic Phenotype -- 4.2.1 Small Gas Molecule Environmental Pollutant Triggers: Phenotype Shapers or Interactors? -- Sulfur Dioxide -- Ozone -- 4.2.2 Volatile Environmental Pollutant Triggers: Phenotype Shapers or Interactors? -- Acrolein -- Butadiene -- 4.3 Particulate Environmental Pollutant Triggers: Phenotype Shapers or Interactors? -- 4.3.1 Tire Breakdown Particles -- 4.3.2 Diesel Exhaust Particles -- 4.4 Summary -- References -- Chapter 5: Current Clinical Diagnostic Tests for Asthma -- 5.1 Introduction -- 5.2 Spirometry -- 5.3 Lung Volumes -- 5.4 Diffusion -- 5.5 Peak Expiratory Flow Rate Measurement -- 5.6 Bronchoprovocative Testing -- References -- Chapter 6: Management of Asthma: The Current US and European Guidelines -- 6.1 The Need for Guidelines -- 6.2 History of the NHLBI Guidelines -- 6.2.1 Adults -- 6.2.2 Children -- 6.3 Summary of Recommendations from the 2007 NHLBI Guidelines -- 6.3.1 Assessing and Monitoring Asthma Control -- 6.3.2 Stepwise Approach for Asthma Management -- Treatment Recommendations for Children 0-4 Years of Age -- Treatment Recommendations for Children 5-11 Years of Age -- 6.3.3 Treatment for Youths ≥12 Years of Age and Adults.
,
6.4 Other International Guidelines -- 6.4.1 The BTS Guidelines -- Initial Assessment and Monitoring -- Pharmacologic Management -- 6.4.2 The GINA Guidelines -- Initial Assessment and Monitoring -- Pharmacologic Management -- 6.4.3 Comparison of Guidelines -- 6.5 The Current Status of Asthma Care and Future Directions -- References -- Chapter 7: Community-Based Interventions in Asthma -- 7.1 T1 to T4 Research: From Bench to Curbside -- 7.2 Public Health Interventions for Asthma -- 7.2.1 Role of Community Coalitions -- 7.2.2 Patient and Provider Education -- 7.3 Asthma, the Environment, and Respiratory Health -- 7.4 Systems Changes -- 7.5 Challenges in Real World Assessment of Program Impacts -- 7.6 Summary -- References -- Chapter 8: Heterogeneity of Response to Therapy -- 8.1 Introduction -- 8.2 Variation in Response to Corticosteroids -- 8.3 Variation in Response to Leukotriene Pathway Inhibitors -- 8.4 Variation in Response to Beta-Receptor Agonists -- 8.5 Variation in Response to Biologic Agents -- 8.6 Summary -- References -- Part II: Genetics and Genomics in Asthma -- Chapter 9: Introduction to Genetics and Genomics in Asthma: Genetics of Asthma -- 9.1 Evidence for a Genetic Basis to Asthma -- 9.1.1 Familial Aggregation of Asthma -- 9.1.2 Inheritance Models for Asthma -- 9.2 Linkage Studies for Asthma -- Box 9.1 An overview of the concepts in linkage and association analysis for the discovery of asthma susceptibility loci -- 9.3 Association Studies for Asthma -- 9.3.1 The Candidate Gene Approach -- 9.3.2 The Genome-Wide Association Approach -- 9.4 Gene-Environment Interactions in Asthma -- Box 9.2A Ignoring gene-environment interactions can mask genetic effects and thereby lead to the genetic heterogeneity between populations in the evaluation of a single genetic locus.
,
Box 9.2B Complexity in models of gene-environment interaction (adapted from Khoury et al. 1988) -- Box 9.2C Established gene-environment interactions in asthma (reviewed in Ober and Yao 2011) -- 9.5 The Next Frontier of Association Studies: DNA Sequencing -- 9.6 Heterogeneity in Asthma Genetics -- Box 9.3 The genomewide association (GWA) approach -- References -- Chapter 10: Gene Expression Profiling in Asthma -- 10.1 Introduction -- 10.2 Applications of Transcriptomics in Asthma Research -- 10.2.1 Immune System Genomic Profiling Studies -- 10.2.2 The Pulmonary Compartment -- 10.3 Methods -- 10.3.1 Tissue Sampling and RNA Isolation -- 10.3.2 Sample Profiling (Table 10.4) -- Platform Considerations -- Oligonucleotide Microarrays -- Next-Generation Sequencing -- Sample Processing Considerations -- 10.3.3 Analytical Considerations -- Quality Control Assessment -- Preprocessing -- Feature Selection -- Experimental Analysis -- Differential Gene Expression Analysis -- Network Modeling -- Clustering Algorithms and Machine Learning Approaches -- RNA-Seq Analysis -- Postanalysis Considerations -- References -- Chapter 11: Asthma Epigenetics -- 11.1 Introduction -- 11.2 DNA CpG Methylation -- 11.3 Histone Modification -- 11.4 MicroRNAs -- 11.5 Telomere Length -- 11.6 Assay Methods -- 11.6.1 DNA CpG Pyrosequencing -- 11.6.2 CpG Genotyping -- 11.6.3 ChIP-seq -- 11.7 Future Directions -- 11.8 Conclusion -- References -- Part III: Proteomics, Metabolomics, and SystemsBiology of Asthma -- Chapter 12: Overview -- 12.1 Introduction -- 12.2 Metabolomics of Asthma -- 12.3 Methods of Sample Preparation for Proteomic Analysis of Airway Samples -- 12.4 Measurement of the Innate Immune Response in the Airway -- 12.5 Functional Proteomics for the Detection of Impaired Cellular Response to Glucocorticoids -- Chapter 13: Metabolomics in Asthma -- 13.1 Introduction.
,
13.2 Current Literature on the Metabolomics of Asthma -- 13.3 Sample Collection and Preparation Methods -- 13.3.1 Exhaled Breath Condensates -- 13.3.2 Sample Preparation -- 13.3.3 Separation Methods -- 13.4 Instrumental Methods -- 13.4.1 Nuclear Magnetic Resonance Spectrometry -- 13.4.2 NMR Studies on Exhaled Breath Condensates -- 13.4.3 NMR Advantages -- 13.4.4 NMR Disadvantages -- 13.5 Mass Spectrometry -- 13.5.1 MS Advantages -- 13.5.2 MS Disadvantages -- 13.6 eNose -- 13.7 Conclusions and Projections -- References -- Chapter 14: Proteomic Analysis of the Asthmatic Airway -- 14.1 Introduction -- 14.2 Sample Types, Collection, and Studies -- 14.2.1 Bronchoscopic Microsampling -- 14.2.2 Epithelial Cells and Epithelial Lining Fluid -- 14.2.3 Bronchoalveolar Lavage Fluids -- 14.2.4 Induced Sputum -- 14.2.5 Exhaled Breath Condensate -- 14.3 Analytical Procedures -- 14.3.1 BALF -- 14.3.2 IS -- 14.4 Future Directions -- References -- Chapter 15: Measurement of the Innate Immune Response in the Airway -- 15.1 Introduction -- 15.2 The Structure of the Innate Immune Response Signaling Pathway -- 15.2.1 The Toll-Like Receptors -- 15.2.2 The Retinoic Acid-Inducible Gene (RIG)-I Like RNA Helicases (RLH) -- 15.2.3 Protein Kinase R -- 15.2.4 Downstream Transcriptional Effectors of the IIR -- 15.3 How the IIR Couples to Adaptive Immunity -- 15.4 Viruses and Asthma Exacerbations -- 15.4.1 Bronchiolitis in Children -- 15.4.2 Viral Exacerbations of Asthma -- 15.5 Quantitative Techniques for Measurement of the IIR -- 15.5.1 Pathway Genes: Quantitative Real-Time PCR -- 15.5.2 Pathway Proteins: Multiplex Bead-Based Analysis of Secreted Proteins/Cytokines -- 15.5.3 Pathway Activation: Selected Reaction Monitoring- Mass Spectrometry -- 15.5.4 Quantification of Activation of NF-κB and IRF3 Pathways Using SID-SRM-MS.
,
Quantification of Activated NF-κB/RelA Complex Using SSDNA Aptamer-SID-SRM-MS.
Permalink
